For more information
Ernest A. Bates, M.D., Chairman and CEO
San Francisco, CA, September 24, 2013 -- AMERICAN SHARED HOSPITAL SERVICES (NYSE MKT:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today shared a recent announcement from Mevion Medical Systems, developer of the MEVION S250 Proton Therapy System for cancer treatment. AMS owns an equity interest in Mevion, and will supply a MEVION S250 for the proton center now under construction at MD Anderson Cancer Center in Orlando, in addition to other projects under development:
MEVION S250 at the Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine Moves to Clinical Commissioning
Littleton, MA., September 22nd, 2013 -- Today, Mevion Medical Systems announced moving from acceptance testing to the clinical commissioning phase of its MEVION S250 Proton Therapy System installed at the S. Lee Kling Center for Proton Therapy at the Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine in St. Louis, MO. The MEVION S250 is a unique proton therapy device designed to deliver the same precise, non invasive treatment capabilities and advantages of conventional systems but with a significantly reduced size, improved reliability, efficient clinical workflow and lower implementation and operational costs. This important milestone marks the handover and operational control of the first MEVION S250 to the physics and radiation oncology proton teams from the Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine for clinical commissioning and patient treatment.
Acceptance testing is a series of demanding tests designed to independently put the MEVION S250 through its paces, carefully validating that technical and clinical performance specifications are met and that the system is ready for clinical commissioning. The Washington University physics team led by Eric E. Klein, PhD, chief of proton therapy physics, performed these tests over a three month period. "The results of our testing confirm that the MEVION S250 is ready to move into the clinical commissioning phase," said Dr. Klein. "We are excited to be in final clinical preparation for our first patient treatment later this year," added Jeffrey D. Bradley, MD, Washington University radiation oncologist and director of the S. Lee Kling Center for Proton Therapy.
The MEVION S250 proton therapy system at the Siteman Cancer Center is the first of many Mevion single room systems to come on line in the United States. "The MEVION S250 has forever changed the economics and accessibility of proton therapy, delivering the only modern, advanced and practical proton therapy solution with a footprint similar to a conventional radiation therapy vault such that it can be integrated within any cancer center," said Joseph K. Jachinowski, chief executive officer of Mevion Medical Systems. Two additional MEVION S250 proton therapy systems have been delivered and are under installation at Robert Wood Johnson University Hospital in New Brunswick, NJ, and at the Stephenson Cancer Center at Oklahoma University in Oklahoma City, OK, with clinical start scheduled for next year. A fourth center at First Coast Oncology in Jacksonville, FL, has completed the facility construction and is already under installation with major gantry components already installed. The MEVION S250 at the MD Anderson Cancer Center in Orlando is under construction and will be completed and ready for system components installation early next year. In addition, University Hospitals in Cleveland, OH just held their groundbreaking ceremony to commence construction of their new proton therapy center.
Mevion is showcasing the MEVION S250 and educating clinicians about the benefits of Practical Proton Therapy at the 55th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in Atlanta, GA from September 22nd to the 24th.About Mevion Medical Systems
Mevion Medical Systems, Inc. is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinical reality.
Mevion's flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.
Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan.
Visit us at: www.mevion.comAbout AMS
American Shared Hospital Services provides turnkey technology solutions for advanced radiosurgical and radiation therapy services. AMS is the world leader in providing Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations and trigeminal neuralgia (facial pain). The Company also offers the latest IGRT and IMRT systems, as well as its proprietary Operating Room for the 21st CenturySM concept. AMS owns common stock in Mevion Medical Systems, Inc., developer of the compact MEVION S250 Proton Therapy System.Safe Harbor Statement
This press release may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services, which involve risks and uncertainties including, but not limited to, the risks of the Gamma Knife and radiation therapy businesses. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2012, the Quarterly Report on Form 10-Q for the quarters ended on March 31, 2013 and June 30, 2013, and the definitive Proxy Statement for the Annual Meeting of Shareholders held on June 11, 2013.Back to Top